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A better-shared care between on one side the general practitioners or chest
physicians and on the other side the patients and their closest surroundings of care
has to be implemented in future guidelines. Guidelines are based on efficacy and not
effectiveness studies, and do not properly focus the process of behavioural changes
of health care professionals and patients. Primary care physicians treat the vast
majority of patients with chronic airway disease of moderate severity. However, they
find the evidence-based practice guidelines often complicated. Furthermore, less
than 50% of the recommendations in guidelines may be evidence based. As rapid
changes may occur in diagnosis and treatment options, future guidelines must be
able to adapt to such rapid adjustments. No randomised studies are available on the
effect of patient-relevant outcomes using guidelines on management of obstructive
lung disease. More outcome research is necessary on both change of procedures and
health endpoints after launching guidelines. Cost-effectiveness studies are
important to make medical staff and administrative health care systems cooperate
in the construction of future health care systems with both an improved medical and
system quality.
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The main goals of the guidelines of obstructive lung
disease (asthma and/or chronic obstructive pul-
monary disease (COPD)) are to achieve better
service and standards for diagnosis, treatment,
care and self-management, which should improve
quality of life and prolong life time for individuals
with chronic respiratory diseases. The major
challenge is thus to develop user-friendly clinical
guidelines that are easily understood and imple-
mented by trainee physicians, general practitioners
and patients. In the search for evidence, the focus
is, however, on strictly designed randomised con-
trolled trials that may detract from the crucial role
played by patients in their own care. The colla-
boration between on one side the general practi-
tioner or chest physician and on the other side the
well disease-educated patient and his or hers
relatives is rarely handled in a practical manner
in the guidelines.
There are a growing number of Nordic asthma
and COPD guidelines generated singularly and
jointly by many national bodies, regional institu-
tions or leading medical persons, all of which offer
recommendations for the diagnosis and manage-
ment of obstructive lung diseases. Almost all of
these have been produced during the last 25 years.
Today there is no sign that their numbers either as
new statements or in revised forms are diminishing.
These documents are important as they act as
benchmarks against which current practice of0
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Figure 1 Annual number of new publications with key words
Guidelines’’ (stippled line) identified through PubMed searchasthma and COPD care is judged. They are also
used as guides to what should or should not be
funded in health care systems. But the increasing
involvement of the medical industry in the devel-
opment of such guidelines may cause serious
restrictions for their use in various national health
care systems where the majority of costs are paid
by taxes. It is also important to recognise that some
experts may have connections to the medical
industry that may reflect their decisions in the
panels. It is very important to be aware of the
strength and limitations of the guidelines and
relate their contents to the individual physician’s
approach to management of obstructive lung
disease.
As the production of clinical guidelines became
an industry of the nineties (Fig. 1), it was initially
thought that physicians would follow those recom-
mendations where the best evidence was distilled
into single documents. However, the last decade
has shown us the increasing importance of imple-
mentation of these guidelines. We have all learnt
that change of management and treatment by
physicians is not solemnly achieved by the produc-
tion of guidelines. Further, the regular general
practitioners may now have to use more than
hundred guidelines, while a consultant in respira-
tory medicine may have 20 guidelines.
We wish to examine several features common to
guidelines used in the Nordic countries for obstruc-
tive lung disease management, consider areas
where their recommendations may change and1999 2000 2001 2002 2003 2004
Year
‘‘Asthma AND Guidelines’’ (drawn line) and ‘‘COPD AND
.
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care based on a more effective implementation.History
Individual review articles and text books have
advocated approaches to asthma and COPD care for
a long time. The first documents were expert
consensus statements, reflecting knowledgeable
but potentially selected reviews of the literature
by the participants. One of the first guidelines in the
Nordic countries was those developed for asthma and
cough by the Swedish ‘‘Social styrelsen for la¨keme-
delinformation’’1 with Norwegian counterparts.
Finland has been a forerunner in the Nordic
countries in developing National programs for
Asthma and COPD. The success factor in Finland
was the firm involvement of the Ministry of Social
Affaires and Health, who created a platform for
both a good system quality and medical quality in
the handling of asthmatics and COPD patients at
the community level.2 The Finnish programme on
asthma emphasises the role of the primary health
care team, with one general practitioner and one
nurse in each municipal health centre who are
trained to work as coordinator of local activities
and taking part in counselling follow-up of patients.
Training of all general practitioners was undertaken
at national, regional and local levels, with 25 000
health care professionals receiving training in the
first 5 years of the programme.3 Moreover, Finnish
Medical Society Duodecim has launched evidence-
based guidelines for COPD in 1999, asthma in 2000
and smoking cessation in 2002 based on systematic
review of the literature by the leading experts of
the country. Asthma and COPD guidelines have
been recently updated. These web-based guide-
lines are short (4–5 pages) with links to more
detailed recommendations and easily accessible via
internet (www.kaypahoito.fi). Every health centre
has access to these recommendations, which has
also been shown to significantly improve the
implementation of the local programmes of these
same diseases. In addition to the recommendations
intended to the professionals, short web-based
guidelines were prepared for the patients.
In Norway, Asthma schools were introduced in the
1990s and in 1999 the National Plan for Asthma
Schools (NPAS) was launched. Its medical content
originated from GINA.4 NPAS developed and im-
plemented separate asthma education packages for
adults, adolescence and children and also opened a
website for teenagers (www.asthmasurf.com) and a
PC program for primary care to help the generalpractitioners handle asthma and COPD and differ-
entiate between them.
The Nordic consensus report on asthma manage-
ment was based on a consensus of expert opinions
and not on a systematic literature survey.5 An
implementation plan for practical use was not
developed for this guideline.
In asthma as well as in COPD, the large interna-
tional professional societies formulated their views
about management, the most important being
those of the European Respiratory Society (ERS)
and the American Thoracic Society (ATS).6 Finally, a
group organised by the World Health Organisation/
National Hearth Lung and Blood Institute in USA
was founded and detailed recommendations were
available through the Global Initiative against
asthma4 and the Global Initiative for Chronic
Obstructive Lung Disease.7 The first editions of
these documents were available in 1995 and 2001,
respectively.
The aims and key features of the GOLD pro-
gramme represent a further advance. GOLD objec-
tives were firstly, to, increase awareness of COPD
among health professionals, health authorities and
the general public, secondly, to improve diagnosis
management and prevention and, thirdly, to sti-
mulate research. The documents have been widely
distributed and national delegates of the GOLD
programme have given regular feedbacks to the
guidelines at the annual ATS and ERS meetings.Grading quality of evidence and strength
of recommendations
The scaling adopted for strength of evidence was
initially relatively simple and will not meet the
more recent and rigorous approaches advocated for
evidence-based medicine. However, the criteria to
assign evidence may differ in steering committees
of the various guidelines. Furthermore, some
groups advocate that meta-analyses or post hoc
analyses of pooled randomised clinical trials are
insufficient to provide definite statistically
significant answers to main clinical questions,8
while others emphasise the conclusions from the
Cochrane Library.9
The present Swedish Guidelines for a national
programme for COPD10 are based on evidence from
multiple systematic reviews or relevant studies.11
The Swedish Council on Technology Assessment in
Health Care selected only mortality, health-related
quality of life, symptoms, need for increased
medication, emergency visits or hospital admissions
as important outcome variables and excluded
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Studies of high quality were defined as (1) randomised
and controlled or a quality-controlled, systematic
review of such studies; (2) report on at least one of
the four primary outcome variables and (3) use a
treatment period of at least 3 months. The bases for
conclusions of effects (positive, no or questionable)
were defined on a four-grade scale (strong, moderate,
weak or little or no support). It is impressive that less
than half of the knowledge on treatment effects
regarding asthma and COPD is strongly supported by
documented evidence.11 The committee concludes
that effects of interventions and drugs for mainte-
nance treatment of COPD are poor.
The process recently applied by the British
National Institute of Clinical Excellence (NICE)9 to
develop the COPD guideline was profound. It was
produced by a development group with 16 persons
(physicians, nurses, physiotherapists and patients)
who met regularly over an 18-months period. All
recommendations were then voted on by a larger
multiprofessional group (the consensus reference
group). The recommendations were graded in three
types: strong evidence, good evidence and no
evidence. The hierarchy of evidence was reflected
in eight groups. The final draft was sent to
stakeholders (i.e. executive committee of the
professional societies who appointed their represen-
tatives) for comments and also placed it on website.
NICE has its own guideline review panel that deals
with both the content of the guidelines and
methodology. However, a recent critical appraisal12
of six existing systems for grading quality of
evidence and strength of recommendations con-
cludes that there was poor agreement about the
sensibility of the systems. The raters showed low
reproducibility of judgements made using different
systems. Thus, some subjectivity, especially regard-
ing recommendations seems unavoidable.
A novel feature of guidelines is the regular
review of new scientific evidence and annual
web-based updates of the original recommenda-
tion. As revisions of guidelines may take time,
existing guidelines may delay funding of newly
evidence-based diagnostic aids and treatments.
Despite the advantage of existing international
documents, it is still appropriate for local mod-
ifications to take place. Resources will vary from
country to country and the pattern of implementa-
tion is likely to be influenced by the existing
methods of physician’s reimbursement and patient
referral. However, the quality control of local
or regional modifications of the international
guidelines may be much poorer. Few of those
describe the people or the techniques applied to
develop the local guidelines for general practi-tioners (Table 1). The costs of various international
programmes and guidelines (diagnosis, drugs, edu-
cation) should be estimated and stated when
implemented locally. This may in future be a
prerequisite from the payers and the health
management system.
A recent handbook, written by the International
primary care airways group, organises the process
of managing chronic airway diseases from Global
Initiative for Asthma,4 the Global Initiative for
Chronic Obstructive Lung Disease7 and Allergic
Rhinitis and its Impact on Asthma13 into tracks that
are tailored to the general practice setting.14 It
describes an approach to diagnosis that helps the
general practitioner to diagnose asthma, COPD
and/or allergic rhinitis based on the patient’s
presenting symptoms and responses to a set of
newly developed questionnaires and diagnosis aids.
The feasibility of these instruments has not been
thoroughly examined in the Nordic countries.Defining obstructive lung diseases
A strict separation of adult patients with asthma or
COPD is often not possible in clinical practice.
Similar symptoms and signs are often present in
both phenotypes of obstructive lung disease. When
using the defining criteria in the guidelines of
asthma and COPD, a large fraction of the patients
can be defined as having both diseases. The
statements in guidelines of effects of interventions
lack mostly the narrow inclusion and exclusion
criteria for the phenotypes of obstructive lung
disease which gave the evidence for a specific
recommendation.
Major symptoms of asthma are attacks of breath-
lessness and wheezing that may occur during both
daytime and night. However, many patients with
variable airflow obstruction may not have such
clearcut symptoms and many individuals in the
community report these symptoms without having
variable airflow obstruction.15
COPD guidelines emphasise airflow obstruction
(reduced FEV1/FVC ratio) and lack of a large
spontaneous variability. The definition does not
account, however, for the heterogeneity of the
disease and does not necessarily differentiate
between ‘‘normal’’ ageing of the lung and disease.16
The availability of quantitative computer tomo-
graphy scanning may in the future provide a
necessary stimulus to create greater knowledge
into studies of the mechanisms of emphysema and
air wall thickness. A prerequisite is that lung
density measurement can be standardised and
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Table 1 Guidelines of obstructive lung disease frequently applied in the Nordic countries in 2005.
Denmark
1. Diagnostik og behandling af KOL i almen praksis, http://www.irk.dk/dk/publikationer/
vejledninger/kol_rev.htm
2. Diagnostik og behandling af asthma bronchiale hos voksne. http://www.dadlet.dk/
klaringsrapport/2002-03/2002-03.htm
Finland
1. Finnish Respiratory Society. Summary of the updated guidelines for chronic obstructive
pulmonary disease. Duodecim 2003;119:2523–4 or http://www.kaypahito.fi
2. Finnish respiratory, allergology and pediatric societies: the diagnosis and treatment of
asthma. Duodecim 2000;116:2568–84, revised 2005 or http://www.kaypahito.fi
Iceland
1. Global initiative for chronic obstructive lung disease, NIH, National heart, lung and Blood
institute. Publication number 2701, April 2001
2. Global initiative for asthma. NIH, National heart, lung and blood institute. Publication
number 02-3659. Revised 2002
Norway
1. Norsk legemiddelha˚ndbok for helsepersonell 2004. Obstruktiv lungesykdom. Foreningen for
utgivelse av Norsk legemiddelha˚ndbok, Oslo ISBN 82-90732-08-2, 2004, p. 326–40. or
www.legemiddelhandboka.no
2. Den norske legeforenings strategigruppe for KOLS. Veileder til diagnose, behandling og
forebygging av kronisk obstruktiv lungesykdom (KOLS), Oslo ISBN 82-8070-010-2, 2002. p.
1–26. or www.legeforeningen.no
Sweden
1. Nationalt va˚rdprogram fo¨r KOL Kronisk Obstruktiv Lungsjukdom Svenska va˚rdprogramet fo¨r
KOL. Svensk lungmedicinsk Fo¨ring, Hja¨rt-Lungfonden, Hja¨rt- och Lungsjukas Riksforbund.
Uppdatert 2005-09-09. revision 1.4 http://www.slmf.se/kol/
2. La¨kemedlesverket. Farmakologisk behandling av astma. Information fra˚n la¨kemedelsverket
2002;13(2):4–70. http://www.mpa.se/workshops/reko/astma/
farmakol_beh_astma.shtml?SOK=Sk
A. Gulsvik et al.S26validated against traditional clinical outcome vari-
ables, and if proven it may be a new measurement
that is objective, specific and sensitive for mon-
itoring the effect of new drugs on the progress of
emphysema in future randomised clinical trials.17
This approach may solve some definition problems
but may create new diagnostic problems.
We are still ignorant of the role of the various
pathological phenotypes in the natural history of
asthma and COPD. Long-term follow-ups as well as
autopsies and histology are highly necessary for
individuals with different patterns of symptoms,
signs and possible causal environmental factors of
obstructive lunge disease.Classifying disease severity
Clinicians expect the guidelines to offer a practical
approach to grade the severity of the disease and
relate this to management decisions. In asthma,
there has been a relation between the patient’s loadof symptoms and the amount of medications sug-
gested to control symptoms. The repeatability of this
classification has not been thoroughly examined.
A completely different approach has been used in
COPD. Until recently, most guidelines based their
staging on the FEV1 making the generally reason-
able assumption that the lower the FEV1 as a
percentage of prediction, the greater the patholo-
gic and symptomatic severities. This approach has
several limitations. Firstly, spirometry has not been
widely available. This remains a problem, espe-
cially in primary care medicine. Secondly, the
arbitrary boundaries selected for the severity
classification have to be questioned. Patients who
lie close to the selected boundaries may therefore
be reclassified as more or less severe if seen on
different days. Thirdly, the relatively poor relation-
ship between health status and spirometry is
obvious. For example, an individual patient with
an FEV1 of 65% predicted can be more symptomatic
than one who’s FEV1 is 40% predicted. Since the
benefits of bronchodilator therapy and rehabilita-
tion are based on symptomatic improvement rather
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base the management on a specified level of
FEV1.
18 The very severe subgroup of COPD is chosen
to highlight a population where persistent daytime
hypoxaemia is more likely to be found. The
weaknesses of a purely symptom-based method to
identify a hypoxemic patient are overt. More
knowledge must be acquired on the precision,
validity and prognostic values as well as the
applicability on treatment decisions of the present
grading of disease severity of asthma and COPD.Management
There is good agreement between the different
management guidelines regarding goals of treat-
ment in asthma and COPD and how to achieve
these. The objectives are to (a) prevent disease
progression and complications, (b) relieve symp-
toms, (c) improve health status, (d) prevent and
treat exacerbations or attacks of breathlessness,
(e) reduce mortality and (f) minimise side effects
from treatments.4,7 These objectives provide a
useful checklist both of the desirable attributes for
any new treatment and to assess the effectiveness
of an individual treatment strategy.
The four essential principles in medication for
adults with asthma are (1) start effective treat-
ment early, win the patient’s confidence and
improve the outcome, (2) treat according to
disease severity, (3) treat exacerbations early and
(4) educate the patient.3
Since none of the existing medications for COPD
have been shown to cure or modify the long-term
decline in lung function, efforts in treatment have
focus on the use of medications to control
symptoms. Recent guidelines have emphasised
other endpoints such as improvement in health
status, exercise capacity and symptoms scores and
in particular perceived breathlessness. Reducing
the frequency and severity of COPD exacerbations
and asthma attacks during the day or night is also
recognised as an important goal of treatment.
However, the use of health status questionnaires,
exercise tests or symptom scores has not reached
daily practice as they are time consuming and
difficult to apply to individual patients.Drugs
All current guidelines recommend the use of
bronchodilators (beta-2-agonists, anticholinergics
and methylxanthines) for the relief of symptoms.The response of an acute bronchodilatation test
has, however, a limited predictive value for a long-
term effect on other clinical outcomes. However,
despite increased use of inhaled corticosteroids, a
large majority of subjects with symptomatic asth-
ma (especially men and smokers with asthma) do
not use this treatment on daily basis.19 We need,
however, appropriate studies of the safety of the
long-acting beta-agonists with regard to severe
asthma episodes and deaths when those episodes
occur.
The sustained relief of symptoms, improvement
in health status and reduction in exacerbation rates
in asthma and in moderate to severe COPD may
result in a change in the position of long-acting
bronchodilatation drugs in future guidelines to-
wards their use earlier in the course of COPD. The
resultant increase in FEV1 may be relatively small,
but it is often accompanied by large changes in lung
volumes, which is associated with reduced dys-
pnoea. All of the current guidelines recommend the
use of the combination of bronchodilatators in
patients to remain symptomatic. Theophyllines
remain a treatment option in most COPD guide-
lines, but as a second line bronchodilatation
therapy because of their systemic administration,
narrow therapeutic index and their greater poten-
tial for side effects.
Inhaled glucocorticosteroids remain a controver-
sial topic in the management of COPD. There is
considerable evidence that the short course of oral
glucocorticosteroids is a poor predictor of long-
term response to inhaled glucocorticosteroids. The
lack of the effect of inhaled corticosteroids on the
decline in FEV1 has been published from four large
trials and the studies provide sufficient evidence
that inhaled glucocorticosteroids at all stages of
the disease do not influence decline in FEV1.
However, inhaled glucocorticosteroids in asthma
and in severe COPD with several exacerbations per
year do appear to affect symptoms and improve
health status possibly by reducing exacerbations,
asthma attacks and hospitalisation.Patient education, rehabilitation and
nutrition
The effectiveness of patient education has been
clearly demonstrated in a Norwegian randomised,
controlled study.20–22 Education in asthmatics was
found to improve health-related quality of life, to
reduce contacts with primary care physicians and
sick days and to improve steroid inhaler compli-
ance. A dominant cost-effectiveness strategy was
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asthmatic at a lower cost in societal perspective.
In patients with COPD, patient education reduced
the need for general practitioners consultations
and reduced the need for rescue medication.
There is consensus on the benefit of exercise
training in symptomatic patients with asthma and
COPD at all stages of the disease. In a rehabilitation
programme, it is important to recognise treatable
conditions like cardiac failure, peripheral muscle
dysfunction, reduction in total and lean body mass,
anxiety and poor coping skills.6 Little knowledge is
available on whether repeated rehabilitation
courses enable patients to sustain the benefits
gained from the initial course of treatment. Home
ventilation as non-invasive ventilation of severe
COPD has so far not been recommended in any of
the guidelines. Guidelines have a role in advocating
the use of pulmonary rehabilitation, since in many
countries pulmonary rehabilitation is only available
in a minority of respiratory centres in spite of the
fact that the evidence is overwhelming in support
of a beneficial effect of pulmonary rehabilitation
on health status. Indeed, the improvement in
health status and exercise tolerance following
pulmonary rehabilitation outstrips many of the
pharmacologic interventions in COPD.Exacerbations and acute attacks of
breathlessness
Impact of exacerbations of COPD and severe
attacks of asthma on health care utilisation and
the detrimental effects on the health status of
patients is emphasised in all guidelines. Important
targets for therapeutic interventions are attacks of
asthma and exacerbations. Similar pathologic pat-
terns have been observed in severe asthma attacks
and exacerbations of COPD.
Asthma attacks should be recognised earlier and
treated promptly with glucocorticosteroids. The use
of antibiotics in exacerbation of COPD remains
somewhat controversial. Although, there is an
increasing evidence that supports their use in
exacerbation with clinical signs of airway infection
defined as increased sputum volume, purulence and
increased breathlessness. Recent studies have shown
significant benefit of oral glucocorticosteroids in the
treatment of exacerbations of COPD. The guidelines
give criteria for hospitalisation, admissions to an
intensive care unit and inpatient oxygen therapy, but
the recommendations are not well documented.
There is now also a consensus for the use of non-
invasive ventilation in COPD, but the exact timing ofthis intervention is unclear. Mortality has been
reported to be lower in patients receiving non-
invasive positive pressure ventilation for COPD than
in those receving both conventional mechanical
ventilation and optimal medical therapy alone.6Implementation
Major gaps in knowledge of diagnosis and treatment
of obstructive lung disease have been shown in
general practitioners and hospital doctors in the
Nordic countries.23 In spite of recommended guide-
lines, 20% of the doctors did not perform any kind
of spirometry when diagnosing obstructive lung
disease. Many health professionals do still only use
symptomatic and physical criteria to define dis-
ease. Only about 35% of the physicians required
spirometry to measure the effects after inhalation
of bronchodilators or corticosteroids. A correct
diagnosis is a prerequisite for giving precise
treatment. Many cases of mistaken diagnosis have
been leading to erroneous treatment.24 The gap
between guidelines and reality is in alignment with
the gap between efficacy and effectiveness studies.
Many physicians are not giving smoking cessation
counselling and not administering influenza and
pneumococcal vaccination to COPD patients. Pul-
monary rehabilitation is recommended only by a
minority of the doctors.25 Small differences were
observed in the diagnosis and treatment between
health professionals of general internal medicine
and general practitioners or between private and
hospital practices and between board-certified
physicians and those in training. Data from several
studies26 have demonstrated that the health ser-
vices change by slow evolution and not by revolu-
tion—humans are generally resistant to change.
Changing clinical behaviour is much more than
writing guidelines. Previous efforts to get the
physician to follow guidelines have overlooked the
importance of clear and concise recommendations.
Guidelines that are written clearly and specify the
precise behaviours required (i.e. who, what, when,
where and how) are most likely to be implemented.
Specifying the required behaviour also facilitates
audit of behaviour. Behaviour analysis of the
controlling antecedents and the consequences of
implementation may help develop effective inter-
vention. In order to increase the effectiveness of
guidelines, it is suggested that guidelines of the
future guidelines are published in three forms: (1)
comprehensive referenced text containing an ex-
ecutive summary, (2) quick reference guide for
clinicians that contains the key points, presented in
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protocols and (3) educational guide for patients.27
Scientists and teachers of medical students and
physicians should for the future take the increasing
amount of evidence from disciplines other than
medicine, concerning how people learn.
Communication skills should form part of medical
training so that clinicians understand that the
relationship with patients is an alliance or partner-
ship. Attentiveness is required to communicate
well with patients, using open-ended questions in
order to understand their fears and concerns about
the disease and its treatment. No implementation
of guidelines should be recommended without
patient education.
The general practitioners in the local health
communities and the chest physicians in the county
and regional hospitals should review their existing
practice for their management of obstructive lung
disease against the guidelines as they develop their
local health delivery plans. The review should
consider the resources required to implement the
recommendations including people and process
involved. A timeline should be planned, and it is
in the interest of patients that the implementation
timeline is as rapid as possible. If relevant local
clinical guidelines and care pathways are available,
this should be reviewed in the light of new
international guidelines and revised accordingly.
Usual ways to examine gaps between guideline
recommendation and practice are (1) surveys of
general practitioner and physician self-report, (2)
prospective chart review and (3) patient self-
report. Obstacles of previous guideline have been
(1) lack of awareness or willingness to be read by
the health professionals, (2) not clearcut recom-
mendations, (3) wish to interpret the literature
themselves, (4) use recommendations of local
colleagues or (5) the recommendations are not
compatible with current local values. Effective
interventions to alter clinical practice have been
educational outreach visits, combinations of audit
and feedback, reminders, local consensus and
interactive educational meetings.Conclusions
The future guidelines of asthma and COPD manage-
ment must be more dependent on evidence from
effectiveness studies and not only from randomised
controlled trials involving narrowly defined patient
population and conducted by those with a specialist
interest in the disease. There are a number of
ways in which guideline implementation could beimproved: (a) rewriting the guidelines to ensure
that they give clear, concise and specific recom-
mendations; (b) ensuring medical and system
quality and (c) educating patients.References
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